Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients

Medicine and Dentistry

• Therapeutic Procedure 100%
• Chronic Hepatitis C 66%
• Genotype 66%
• Ribavirin 66%
• Patient 66%
• Toxicity 33%
• Antiviral Therapy 33%
• Hepatitis C Virus 33%
• Host Factor 33%
• Peginterferon Alpha 33%
• Peginterferon 33%
• Comprehension 33%
• Clinician 33%
• Assessment 33%
• Medication 33%
• Relapse 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Ribavirin 66%
• Chronic Hepatitis C 66%
• Virus 66%
• Toxicity 33%
• Host Factor 33%
• Peginterferon Alpha 33%
• Hepatitis C Virus 33%
• Peginterferon 33%
• Relapse 33%